NCT05099549View on ClinicalTrials.gov

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions
Squamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsAdvanced Solid TumorRefractory TumorMetastatic Tumor
Interventions
DRUG

AFM24

Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

BIOLOGICAL

SNK01

Patient-specific ex-vivo expanded autologous natural killer cells.

Trial Locations (3)

60611

University of Chicago, Chicago

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

90403

Sarcoma Oncology Center, Santa Monica

Sponsors

Collaborators (1)

Affimed GmbH
All Listed Sponsors
collaborator

Affimed GmbH

INDUSTRY

lead

NKGen Biotech, Inc.

INDUSTRY

NCT05099549 - Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Biotech Hunter | Biotech Hunter